HC Wainwright Reiterates Neutral Rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “neutral” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports.

A number of other brokerages also recently commented on EYPT. Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday. Jefferies Financial Group decreased their price target on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a report on Monday. Royal Bank Of Canada lowered their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $4.87 on Tuesday. Eyepoint Pharmaceuticals has a 1 year low of $3.95 and a 1 year high of $19.11. The company has a market capitalization of $419.84 million, a PE ratio of -1.30 and a beta of 1.76. The company has a fifty day moving average of $13.10 and a 200 day moving average of $13.62.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Research analysts expect that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several hedge funds have recently modified their holdings of EYPT. Stempoint Capital LP grew its position in shares of Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after acquiring an additional 456,915 shares during the period. Janus Henderson Group PLC raised its holdings in Eyepoint Pharmaceuticals by 22.6% in the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares during the period. California State Teachers Retirement System raised its holdings in Eyepoint Pharmaceuticals by 2,158.3% in the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after purchasing an additional 100,447 shares during the period. The Manufacturers Life Insurance Company boosted its position in Eyepoint Pharmaceuticals by 58.4% during the first quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock worth $465,000 after purchasing an additional 13,297 shares in the last quarter. Finally, Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals during the first quarter worth approximately $36,414,000. 99.41% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis that excluded an asymmetric cohort of nine patients whose vision loss was considered unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, strong anatomic control through Week 56, supplement-free treatment rates and a favorable redosing safety profile. EyePoint Announces Topline Data from LUGANO
• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, while Chardan reaffirmed its “buy” rating and $65 target. These bullish views indicate some analysts believe the LUGANO result may be addressable and that DURAVYU’s longer-duration treatment profile retains value.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the trial results were released, reflecting the material importance of the announcement. JPMorgan reaffirmed its “neutral” rating.
• Negative Sentiment: The full trial dataset did not meet the primary endpoint because the unusual vision-loss cohort affected the result. Investors now face greater regulatory and clinical uncertainty, particularly while awaiting the second pivotal Phase 3 trial. EyePoint’s eye drug misses main goal in late-stage trial
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral.” The setback prompted speculation that competing ophthalmology companies, including Ocular Therapeutix and Forma Therapeutics, may now appear more attractive, further pressuring EYPT’s valuation.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.